News

NASDAQ: ABVC

Press Releases

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

 ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study 150 150 Press Release
  • Press Release

FREMONT, CA, Dec. 07, 2023 (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company’s eight-week long ADHD Phase II part II clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. A total of 94 subjects were screened, out of which 69 enrolled in the study; 60 subjects completed the eight-week study. The study entitled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part II” is a randomized, double-blind, placebo-controlled…

A Natural Approach to Alleviate Depression in Cancer Patients with Dr. Scott Irwin

 A Natural Approach to Alleviate Depression in Cancer Patients with Dr. Scott Irwin 1858 976 ABVC

https://www.youtube.com/watch?v=QZ754OpWC7E In this video we talk wit Dr. Scott Irwin from Cedar-Sinai Medical Center. He shares insights on how we use a natural and herbal way to treat Depression in Cancer Patients. Scott A. Irwin, MD, PhD, FCLP, FAPA is professor of Psychiatry. He is currently the Director of the Patient and Family Support Program at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute. His pioneering work involves exploring the potential of natural and herbal remedies in addressing the complex emotional challenges faced by individuals battling cancer. In this video he talks about his work with ABVC during the Phase I Clinical…

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

 ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M 150 150 Press Release

FREMONT, CA, Nov. 16, 2023 (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company’s CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the “Licensed Products”). The agreement has the potential of licensing income worth $467M and royalties up to $200M. The Licensed Products for MDD and ADHD, owned by ABVC and its subsidiary BioLite, Inc., were valued at $667M by a third-party evaluation. ABVC and…

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

 ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results 150 150 Press Release

FREMONT, CA, Nov. 15, 2023 (NASDAQ: ABVC) (“Company”): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023. These results, including the financial statements included herein, can be found in the Company’s Quarterly Report on Form 10-Q that was filed earlier today with the Securities and Exchange Commission Third Quarter 2023 Financial Results All comparisons are made on a year-over-year basis. Shareholders’ Equity On February 23, 2023, the Company entered into a securities purchase agreement with Lind Global…

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

 ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million 150 150 Press Release

FREMONT, CA, Oct. 26, 2023 — (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with AiBtl BioPharma (AiBtl) for the Company’s CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the “Licensed Products”). The potential license will cover the Licensed Products’ clinical trial, registration, manufacturing, supply, and distribution rights. The Licensed Products for MDD and ADHD, owned by ABVC and its subsidiary BioLite, Inc., were valued…

NEW: Summer 2023 Investor Presentation

View the latest product information, status updates, financial information, and more.

VIEW PRESENTATION
PRESS RELEASES
SEC FILINGS
INVESTOR CONSIDERATIONS
CONTACT ABVC
SAFE HARBOR STATEMENT

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company’s operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by ABVC, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Investor Considerations

  • Strong portfolio of medicines and medical devices addresses wide range of disorders.
  • In 2022, Vitargus is expected to begin a global pivotal trial, the final step leading to marketing in collaboration with big pharma licensing partners.
  • MDD drug intended to reduce adult depression completes Clinical Phase II with results exceeding expectations.
  • Botanical expertise leads to medicines with fewer side effects.
  • Partnerships with some of the most prestigious researchers in the world enhances the value of clinical trial results.
  • Business model designed to minimize burn rate.
  • Less than 30 million shares outstanding.

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.